Medigene Immunotherapies GmbH

Planegg/Martinsried, May 4, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents the webtool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), taking place May 3-5, 2023, in Mainz, Germany. The Expitope webtool originates from a long standing collaboration between Medigene Immunotherapies GmbH and Prof. Dmitrij Frishman of the Faculty of Bioinformatics and his research team at the Technical University Munich. Through this joint endeavor, deep academic expertise in sophisticated bioinformatics, is applied for in silico assessment of potential target antigens for T cell receptor engineered T cell (TCR-T) therapies for treatment of solid cancer. The webtool now coupled with artificial intelligence, draws from the vast and continually expanding data on the human genome and proteome of diverse tumors and healthy tissues. This webtool enables Medigene to employ cutting edge in silico technologies to efficiently investigate selected proteins and associated peptide epitopes as suitable targets for use in TCR-T therapies for selected cancer indications. The poster and oral presentation entitled, “Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLAEpitope Prediction and Safety Assessment” will showcase the latest, publicly available version of Expitope 3.0, a faster and fully revised webtool, which will be launched in May/June 2023, to identify the target peptide HLA (pHLA) epitopes in antigens. Comparing pHLA epitope expression in various healthy tissues allows to predict potential cross-reactivity and off-target toxicity thereby minimizing safety risks. The poster and the presentation will be available on Medigene’s website: Expitope 3.0 users can identify pHLA epitopes that could be suitable targets for TCR isolation and prediction of pHLA binding affinities as well as related epitopes with up to 50% mismatch for safety evaluation through the assessment of their expression patterns in healthy tissues. Expitope 3.0 comes with an updated database, screening additionally for unique sequences on peptidome/transcriptome level thereby enlarging the number of screened epitopes. The webtool utilizes machine learning to improve pHLA epitope binding prediction. An improved epitope prediction function provides higher accuracy in determining proteasomal/immunoproteasomal cleavage and presentation of epitopes. In summary, Expitope 3.0 allows for a quicker analysis with a broader search of databases and higher prediction accuracy of pHLA epitopes in antigens. Its improved features and capabilities make it a valuable tool for researchers and clinicians working to identify potential targets for T cell therapies while minimizing safety risks. “Antigen selection and assessment of on and off-target specificity is a major challenge in generation of TCR-T therapies. To make such selections and reduce off-target toxicity the identification of suitable epitopes is the first and most critical step for creation of best-in-class TCR-T therapies,” said Dolores Schendel, Chief Scientific Officer at Medigene. “Expitope 3.0 is now available through our joint collaboration with Prof. Frishman and his research team to enable us to employ this faster and fully revised webtool encompassing information in greatly expanded owing us not only to screen for unique sequences as potential targets for T cell therapies but also to predict characteristics of peptide interactions with HLA molecules and their safety profiles in healthy tissues. . Use of this advanced tool increases understanding of the safety pro for generation of highly differentiated TCR-T therapies that can address the unmet needs of patients with diverse solid tumors. We are pleased that this long standing collaboration allowed this updated webtool to be developed to better meet these needs.” --- end of press release --- About Medigene Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit About Medigene’s End-To-End Platform Medigene’s immunotherapies help activate the patient’s own defense mechanisms by harnessing T cells in the battle against cancer. Medigene’s end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, Precision Pairing) and development optimization technologies (e.g. Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2seventy bio, and Hongsheng Sciences, continue to validate the platform’s assets & technologies. This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. Medigene Pamela Keck Phone: +49 89 2000 3333 01 E-mail: investor@medigene.com LifeSci Advisors Sandya von der Weid Phone: +41 78 680 05 38 E-mail: svonderweid@lifesciadvisors.com In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

Martinsried/Munich and Hong Kong (pta/04.04.2019/12:38) - Cytovant licenses East Asian rights for a research-stage T cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene's dendritic cell (DC) vaccine for the treatment of patients across East Asia Cytovant and Medigene to collaborate on research and discovery of two additional TCRs tailored for patients in East Asia Medigene receives an upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestones and low double-digit royalties John Xu, PhD, former President and Chief Scientific Officer of Mab-Legend Biotech, named President of Cytovant Roivant Sciences and Sinovant Sciences today announced the launch of Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia. Cytovant will focus on development programs that have the potential to transform the treatment of diseases that are prevalent in Asian patients. Concurrent with the company's launch, Cytovant has entered into a multi-program license and collaboration agreement with Medigene AG, a clinical stage biotechnology company focusing on the development of T cell immunotherapies. Medigene has granted Cytovant exclusive licenses to develop, manufacture, and commercialize Medigene's research-stage T cell immunotherapy targeting NY-ESO-1 as well as a DC vaccine targeting WT-1 and PRAME, in Greater China, South Korea, and Japan. In addition, Cytovant and Medigene have entered into a strategic collaboration and discovery agreement for T-cell receptor (TCR) immunotherapies for two additional targets. Medigene will be responsible for the generation and delivery of the TCR constructs using its proprietary TCR discovery and isolation platform. Following this research collaboration period, Cytovant will assume sole responsibility for the development and commercialization of these TCR therapies in the relevant countries. The TCRs to be generated by Medigene will be tailored specifically to Asian patients. Under the terms of the transaction agreements, Medigene will receive an overall upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestone payments which in aggregate could total over USD 1 billion for the four products across multiple indications. Furthermore, Medigene will be eligible to receive royalty payments on net sales of the products in a low double-digit percentage in the relevant countries. Additionally, Cytovant will reimburse all R&D costs incurred by Medigene within the collaboration. "T cell receptors are the scouts of the immune system," said Prof. Dolores Schendel, CEO/CSO of Medigene. "They help T cells recognize and destroy cancer cells. We use our sophisticated screening systems to generate tailored TCR therapies for patient populations with specific genetic characteristics. This partnership implements Medigene's strategy to discover TCRs with various HLA specificities in order to address different populations and markets. Cytovant, with its highly experienced management and scientific team was launched by Roivant and Sinovant to achieve excellence in cell therapies and we are proud to be part of this story of delivering various TCR projects as well as our DC vaccine for development in East Asia." "The complexities of end-to-end cell therapy manufacturing, development, and commercialization in Asia require regional focus, specialization, and knowledge," said Benjamin Zimmer, President of Roivant Health. "Roivant and Sinovant have built Cytovant precisely to address these scientific and logistical complexities. We are excited to announce this strategic alliance with Medigene, one of the leading companies in the field of T cell-based therapies, to deliver important new cellular immunotherapies to Asian patients as quickly as possible." Dr. John Xu, a molecular immunologist by training and translational scientist, has joined Cytovant and will serve as the company's President. Prior to joining Cytovant, Dr. Xu was President and Chief Scientific Officer of Mab-Legend Biotech, a Shanghai-based antibody discovery company. Previously, Dr. Xu also served as Chief Scientific Officer of Shanghai Benemae Pharmaceutical Corporation and as Head of the Biologics Group at GSK China. He received his B.S. in cell biology and genetics from Peking University and his Ph.D. in biochemistry and molecular biology from Harvard University. "We are thrilled to welcome John to Cytovant," said Dr. Xinan Chen, Executive Chairman of Sinovant. "John's deep scientific expertise and knowledge of Asia's health priorities make him an ideal leader for the company as we prepare to rapidly scale its research and development activities. The launch of Cytovant represents an important milestone in Sinovant's evolution as a platform for entrepreneurs like John and we look forward to building Cytovant with him." About Cytovant Cytovant is a clinical-stage biopharmaceutical company focused on developing innovative cellular therapeutics in Asia. Cytovant's mission is to become Asia's premier cell therapy company by discovering, developing, and commercializing new medicines that are uniquely suited to Asian patients. About Roivant Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit About Sinovant Sinovant is a Chinese biopharmaceutical company dedicated to conducting globally innovative biomedical R&D in China to meet the needs of patients in Greater China and around the world. Sinovant's mission is to develop and commercialize new medicines that address the most pressing public health challenges in China while simultaneously advancing Chinese biopharmaceutical research abroad. For further information, please visit About Medigene Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell receptor-modified T cells (TCR-Ts) and has projects currently in preclinical and clinical development. For more information, please visit Contractual parties to the agreement are Medigene Immunotherapies GmbH, a wholly owned affiliate of Medigene AG, and Roivant Asia Cell Therapy Holdings Ltd., a wholly owned subsidiary of Roivant Sciences Ltd. Forward-Looking Statements This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. Contacts Roivant Sciences Paul Davis Tel: +1 (646) 495-5310 email: paul.davis@roivant.com Sinovant Sciences Qi Gu Tel: +86-10-59407085 email: qi.gu@sinovant.com Medigene AG Julia Hofmann, Dr. Robert Mayer Tel.: +49 - 89 - 20 00 33 - 33 01 email: investor@medigene.com